| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Investigation |
1 Department of Cardiology, University Hospital of Maastricht, Maastricht, The Netherlands; 2 Department of Biochemistry, University of Maastricht, Maastricht, The Netherlands; 3 Department of Clinical Pharmacy, University Hospital of Maastricht, Maastricht, The Netherlands; 4 Department of Nuclear Medicine, University Hospital of Maastricht, Maastricht, The Netherlands; 5 Department of Nuclear Medicine, Maxima Medical Center, Veldhoven, The Netherlands; and 6 Division of Cardiology, University of California, Irvine College of Medicine, Irvine, California
Correspondence: For correspondence or reprints contact: Leo Hofstra, University Hospital of Maastricht, Department of Cardiology, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands. E-mail: L.Hofstra{at}cardio.unimaas.nl
Apoptosis, or programmed cell death (PCD), contributes to the decline in ventricular function in heart failure. Because apoptosis comprises a programmed cascade of events, it is potentially reversible, and timely intervention should delay the development of cardiomyopathy. 99mTc-Labeled annexin A5 has successfully been used for the noninvasive detection of PCD in myocardial infarction and heart transplant rejection. The present study evaluated the role of annexin A5 imaging for detection of PCD in heart failure patients. Methods: Annexin A5 imaging was performed on 9 consecutive heart failure patients with advanced nonischemic cardiomyopathy (dilated, n = 8; hypertrophic, n = 1) and in 2 relatives having the same genetic background as the hypertrophic cardiomyopathy patient but no heart failure. Results: Four of the patients with dilated cardiomyopathy and the 1 with hypertrophic cardiomyopathy and heart failure showed focal, multifocal, or global left ventricular uptake of annexin A5. No uptake was visualized in the remaining 4 patients or in the 2 controls. All cases showing annexin A5 uptake within the left ventricle experienced significant reduction in left ventricular function or functional class. In cases with no annexin A5 uptake, left ventricular function and clinical status remained stable. Conclusion: These data indicate the feasibility of noninvasive PCD detection with annexin imaging in heart failure patients. Annexin A5 uptake is associated with deterioration in left ventricular function, and this association may lend itself to the development of novel management strategies.
Key Words: apoptosis • heart failure • annexin A5
COPYRIGHT © 2007 by the Society of Nuclear Medicine, Inc.
This article has been cited by other articles:
|
|
 |
|
  A. Gonzalez, B. Lopez, S. Ravassa, J. Beaumont, T. Arias, N. Hermida, A. Zudaire, and J. Diez Biochemical markers of myocardial remodelling in hypertensive heart disease Cardiovasc Res, September 20, 2008; (2008) cvn235v2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Narula and V. Dilsizian From Better Understood Pathogenesis to Superior Molecular Imaging, and Back... J. Am. Coll. Cardiol. Img., May 1, 2008; 1(3): 406 - 409. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sarai, D. Hartung, A. Petrov, J. Zhou, N. Narula, L. Hofstra, F. Kolodgie, S. Isobe, S. Fujimoto, J.-L. Vanderheyden, et al. Broad and Specific Caspase Inhibitor-Induced Acute Repression of Apoptosis in Atherosclerotic Lesions Evaluated by Radiolabeled Annexin A5 Imaging J. Am. Coll. Cardiol., December 11, 2007; 50(24): 2305 - 2312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Hofstra and S. Heymans Annexin A5 and the failing heart; lost or found in translation? Eur. Heart J., November 2, 2007; 28(22): 2695 - 2696. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
